3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
97
Thoracic
48
Gynecologic
27
Breast
24
CNS
21
Genitourinary
10
Head & Neck
6
Other solid neoplasm
4
Dermatologic
4
Tumor-Agnostic
2
Plasma cell
1
Other neoplasm
1
NET
1
Lymphoid
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Carcinoma, Neuroendocrine
1
Interventions
lutetium Lu 177 dotatate
4
lanreotide
3
Temozolomide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
(177)Lu-DOTA-EB-TATE
3
anlotinib
2
Positron Emission Tomography Computed Tomography
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Metformin
2
Everolimus
2
Etoposide
2
Cisplatin
2
Capecitabine
2
Biopsy
2
surufatinib
1
sintilimab
1
regorafenib
1
recombinant interferon alpha 2b-like protein
1
pembrolizumab
1
gallium Ga 68 dotatate
1
copper dotatate CU-64
1
cabozantinib
1
amino-acid, glucose, and electrolyte solution
1
Yttrium-90
1
Tomography, Emission-Computed, Single-Photon
1
Thalidomide
1
Tegafur
1
Surgical Procedures, Operative
1
Somatostatin
1
Rose Bengal B
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Bevacizumab
×
NET
×
Clear all
NCT01203306
2010-09-16
XELBEVOCT
University of Turin, Italy
Phase 2
Unknown
42 enrolled